Volume 11, Issue 12 p. 1470-1479
Featured Article

Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem

Christoffer Rosén

Corresponding Author

Christoffer Rosén

Clinical Neurochemistry Laboratory, Department of Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Corresponding author. Tel.: +46-0708-540533; Fax: +46-3141-9289.

E-mail address: [email protected]

Search for more papers by this author
Bahman Farahmand

Bahman Farahmand

Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society (NVS), Karolinska Institutet, Stockholm, Sweden

Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

Search for more papers by this author
Tobias Skillbäck

Tobias Skillbäck

Clinical Neurochemistry Laboratory, Department of Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Search for more papers by this author
Katarina Nägga

Katarina Nägga

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden

Search for more papers by this author
Niklas Mattsson

Niklas Mattsson

Clinical Neurochemistry Laboratory, Department of Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA

Search for more papers by this author
Lena Kilander

Lena Kilander

Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden

Search for more papers by this author
Dorota Religa

Dorota Religa

Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

Center for Alzheimer Research, Division for Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society (NVS), Karolinska Institutet, Huddinge, Sweden

Search for more papers by this author
Anders Wimo

Anders Wimo

Center for Alzheimer Research, Division for Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society (NVS), Karolinska Institutet, Huddinge, Sweden

Search for more papers by this author
Kaj Blennow

Kaj Blennow

Clinical Neurochemistry Laboratory, Department of Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Search for more papers by this author
Bengt Winblad

Bengt Winblad

Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

Center for Alzheimer Research, Division for Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society (NVS), Karolinska Institutet, Huddinge, Sweden

Search for more papers by this author
Henrik Zetterberg

Henrik Zetterberg

Clinical Neurochemistry Laboratory, Department of Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK

Search for more papers by this author
Maria Eriksdotter

Maria Eriksdotter

Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society (NVS), Karolinska Institutet, Stockholm, Sweden

Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

Search for more papers by this author
First published: 13 June 2015
Citations: 15
The authors report no conflicts of interest.

Abstract

Introduction

New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid-β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD-indicative cerebrospinal fluid (CSF) biomarker profile.

Methods

By cross-referencing a laboratory database with the Swedish Dementia Registry (SveDem), 2357 patients with data on CSF Aβ and tau biomarkers and a clinical diagnosis of AD with dementia were acquired.

Results

Altogether, 77.2% had pathologic Aβ42 and total tau or phosphorylated tau in CSF. These results were stable across age groups. Female sex and low mini-mental state examination score increased the likelihood of pathologic biomarkers.

Discussion

About a quarter of clinically diagnosed AD patients did not have an AD-indicative CSF biomarker profile. This discrepancy may partly reflect incorrect (false positive) clinical diagnosis or a lack in sensitivity of the biomarker assays.